Skip to content
RDL Network logo
Preliminary results from a subset of patients (pts) with advanced ovarian cancer (OC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb) — Tarek Meniawy (2017) | RDL Network